Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company. The Company is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. The Company's products have been developed to overcome three significant limitations associated with existing adenovirus based products: i) ineffectiveness in the presence of pre-existing immunity; ii) inability to immunize multiple times against the same disease; and, iii) inability to immunize against multiple diseases in the same person. Benefits of the Etubics Platform products include the following:• Safe and Thoroughly Studied including human trials• Effective in the Presence of Pre-Existing Immunity• CMI Response• Rapid Development• Diverse Product OpportunitiesThe Company has completed Phase I/IIa clinical trials with its lead product, ETBX-011 an immunotherapeutic to treat colorectal cancer. To date, the Company has been very encouraged by the clinical data for ETBX-011 and no safety issues or serious adverse effects (SAE) have been reported in both animal and human studies.